SciSparc and Clearmind Medicine Patent Collaborations

SciSparc and Clearmind Medicine recently saw a significant increase in their shares after filing three patent applications under the international Patent Cooperation Treaty.

SciSparc Surges 43%

SciSparc, a specialty clinical-stage pharmaceutical company, experienced a remarkable 43% surge, reaching $4.99 in stock price.

Clearmind Medicine Rises 17%

Clearmind Medicine, a biotechnology company, also witnessed a positive shift, with their shares rising by 17% to $1.54.

Collaboration Results in Novel Combinations

The patent applications are a result of an ongoing collaboration between the two companies. Initially filed by Clearmind as provisional patent applications with the United States Patent and Trademark Office, these applications focus on innovative combinations involving lysergic acid diethylamide, psilocybin, N,N-dimethyltryptamine, and Palmitoylethanolamide.

Advancing Research in the Psychedelic Industry

Clearmind's Chief Executive, Dr. Adi Zuloff-Shani, expressed enthusiasm about the collaboration's progress. He stated, "Our collaboration with SciSparc has led to the submission of 11 patent applications so far. This positions us at the forefront of research in the psychedelic industry, enabling us to develop more effective and safer treatments."